Cardiac toxicity in children and adolescents with Hodgkin lymphoma after chemoradiotherapy

R. I. Feoktistov; Феоктистов Р. И.; O. A. Schurova; Щурова О. А.; J. G. Abugova; Абугова Ю. Г.; J. Yu. Dyakonova; Дьяконова Ю. Ю.; O. V. Makarova; Макарова О. В.; N. V. Myakova; Мякова Н. В.; N. B. Senyakovich; Сенякович Н. Б.; E. V. Samochatova; Самочатова Е. В.

Cardiac toxicity in children and adolescents with Hodgkin lymphoma after chemoradiotherapy

Authors: Feoktistov R.I.¹, Schurova O.A.², Abugova J.G.², Dyakonova J.Y.², Makarova O.V.¹^,2, Myakova N.V.¹^,2, Senyakovich N.B.², Samochatova E.V.¹^,2
Affiliations:
1. Federal Research Center of Pediatric Hematology, Oncology and Immunology
2. Russian Children Clinical Hospital
Issue: No 1 (2010)
Pages: 31-36
Section: HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CARE
Published: 23.02.2010
URL: https://oncohematology.abvpress.ru/ongm/article/view/646
ID: 646

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

During the last decade in Russian clinics significant success in treatment of children with Hodgkin lymphoma has been reached. However, the using of doxorubicin in combination with mediastinal radiotherapy in cases of initial mediastinum involvement contributes to cardiomyopathy occurrence in different time from ending therapy. We have evaluated the cardiac status in 42 children with Hodgkin lymphoma after chemoradiotherapy. Evaluation of cardiac function was performed using standard M-mode echocardiography (with calculation ejection fraction- EF, left ventricular shortening fraction — FS) and electrocardiography with estimation of rate, rhythm and QTc duration. Reduced contractility was detected in 5 (11.9 %) children after chemoradiotherapy, that requires cardiac function monitoring and cardiologist’s consultation.